Lassa fever is a significant health threat to West African human populations with hundreds of thousands of annual cases. There are no approved medical countermeasures currently available. Compassionate use of the antiviral drug ribavirin or transfusion of convalescent serum has resulted in mixed success depending on when administered or the donor source, respectively. We previously identified several recombinant human monoclonal antibodies targeting the glycoprotein of Lassa virus with strong neutralization profiles in vitro. Here, we demonstrate remarkable therapeutic efficacy using first-in-class human antibodies in a guinea pig model of Lassa infection thereby presenting a promising treatment alternative.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5032844 | PMC |
| http://dx.doi.org/10.1016/j.antiviral.2016.08.012 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Current perspectives on vaccines and therapeutics for Lassa Fever.
Virol J
December 2024
Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, Canada.
Lassa virus, the cause of deadly Lassa fever, is endemic in West Africa, where thousands of cases occur on an annual basis. Nigeria continues to report increasingly severe outbreaks of Lassa Fever each year and there are currently no approved vaccines or therapeutics for the prevention or treatment of Lassa Fever. Given the high burden of disease coupled with the potential for further escalation due to climate change the WHO has listed Lassa virus as a priority pathogen with the potential to cause widespread outbreaks.
View Article and Find Full Text PDFSystematic Review and Meta-Analysis of Female Reproductive Health Following Ebola Virus Disease.
Am J Trop Med Hyg
December 2024
Department of Medicine, Section of Infectious Diseases, School of Medicine, Tulane University, New Orleans, Louisiana.
Article Synopsis
- The systematic review focuses on reproductive health issues faced by female survivors of Lassa fever and Ebola virus disease.
- Thirteen studies reviewed predominantly highlight negative outcomes related to reproductive health among EVD survivors, including menstrual irregularities and pregnancy loss, with no research identified on LF survivors.
- The analysis indicates that about 14% of female EVD survivors experience adverse reproductive health outcomes, revealing a significant need for further research in this area.
U-73122, a phospholipase C inhibitor, impairs lymphocytic choriomeningitis virus virion infectivity.
J Gen Virol
December 2024
Laboratory of Emerging Viral Diseases, International Research Center for Infectious Diseases, Research Institute for Microbial Diseases, Osaka University, Suita, Osaka, Japan.
Lassa virus (LASV) is an Old World (OW) mammarenavirus that causes Lassa fever, a life-threatening acute febrile disease endemic in West Africa. Lymphocytic choriomeningitis virus (LCMV) is a worldwide-distributed, prototypic OW mammarenavirus of clinical significance that has been largely neglected as a human pathogen. No licensed OW mammarenavirus vaccines are available, and the current therapeutic option is limited to the off-label use of ribavirin, which offers only partial efficacy.
View Article and Find Full Text PDFFatal Lassa fever in cynomolgus monkeys is associated with systemic viral dissemination and inflammation.
PLoS Pathog
December 2024
Unité de Biologie des Infections Virales Emergentes, Institut Pasteur, Université Paris Cité, Lyon, France.
Article Synopsis
- - The study explores how Lassa fever develops and the factors that determine whether it results in a mild or severe illness, using a monkey model to replicate different disease outcomes.
- - It finds that lymphoid organs are key early sites for the replication of the Lassa virus, which can enter through lymph node structures regardless of whether the infection is fatal or not.
- - The severity of the disease correlates with how the virus spreads; in nonfatal cases, it largely stays within lymphoid tissues, while fatal outcomes see the virus invade multiple organs, triggering a strong immune inflammatory response.
Molecular detection of dengue virus from febrile patients in Ghana.
BMC Infect Dis
December 2024
Tokyo Medical and Dental University, Tokyo, Japan.
Background: Viral hemorrhagic fevers (VHFs) belong to a group of viral infectious diseases that interfere with the blood's clotting mechanism. VHF has a wide host range, including bats, rodents, or arthropods such as mosquitoes and ticks. Most VHFs emerge suddenly as outbreaks, making it difficult to predict occurrence.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!